Neurocrine Biosciences Inc

13 de ago. de 2026, 20:02 UTC

Neurocrine Biosciences shares decline as Morgan Stanley lowers price target to $182, citing safety concerns over VYKAT XR and reports of serious adverse events.

12 de ago. de 2026, 21:11 UTC

Neurocrine Biosciences published positive KINECT-PRO™ study results, yet shares are lower in after-market hours, continuing a trend of declining daily closes.

10 de ago. de 2026, 19:36 UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, contributing to a rise in shares during the session. The stock remains below its 20-day moving average.

7 de ago. de 2026, 19:46 UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

6 de ago. de 2026, 19:36 UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

5 de ago. de 2026, 23:46 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

4 de ago. de 2026, 19:26 UTC

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

3 de ago. de 2026, 20:51 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

31 de jul. de 2026, 23:56 UTC

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

30 de jul. de 2026, 21:51 UTC

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

29 de jul. de 2026, 18:46 UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

28 de jul. de 2026, 23:41 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

27 de jul. de 2026, 19:21 UTC

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

24 de jul. de 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

22 de jul. de 2026, 19:51 UTC

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

21 de jul. de 2026, 19:51 UTC

Neurocrine shares rise after Guggenheim raises price target to $200.

20 de jul. de 2026, 23:46 UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.